Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

The FDA Proposes Adding Five Of 31 Drug Substances To 503A Bulks List

Sep 05 2019

• By Joanne S. Eglovitch

Smiling pharmacist and indian pharmacy technician posing in drugstore - Image — FDA Proposes To Disallow More Active Substances From Pharmacy Compounding • Source: Shutterstock

Related Content

The US FDA Reverses Decision And Allows Oxitriptan Compounding For Now

Jul 09 2019

FDA Commissioner Outlines Priorities For Tightening Oversight Of Drug Compounding Facilities

Jan 19 2018

FDA Final Rule Places Six Substances On 503A Bulks List; Rejects Four

Feb 20 2019

Nine More FDA Bulk Compounding Denials Proposed Post-Vasopressin

Sep 03 2019

No Means No, US FDA Advises 503A Compounding Pharmacies

May 24 2019

FDA Begins Restricting Bulk Compounding With First DQSA Determinations

Mar 06 2019

Additional Topics

United States Manufacturing Quality Compliance Market Access BioPharmaceutical

More from Manufacturing

More from Compliance

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window